• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国卫生研究院文献>Medicina >Aripiprazole Augmentation to Mood Stabilizers for Obsessive-Compulsive Symptoms in Bipolar Disorder
【2h】

Aripiprazole Augmentation to Mood Stabilizers for Obsessive-Compulsive Symptoms in Bipolar Disorder

机译：Aripiprazole在双相障碍中增强情绪稳定剂对双相情感障碍的强迫症状

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background and Objectives: Aripiprazole is a first-line agent in the treatment of bipolar disorder (BD) and available data demonstrates its efficacy on clinical symptoms in serotonin reuptake inhibitors-resistant obsessive-compulsive disorder (OCD) patients. Therefore, aripiprazole augmentation to mood stabilizers could represent a promising treatment in BD patients with comorbid OCD. The study examined the efficacy and safety of aripiprazole added to lithium or valproate for the treatment of obsessive-compulsive (OC) symptoms in euthymic BD patients with comorbid OCD. Materials and Methods: This is a 12-week prospective observational study. The efficacy of aripiprazole on OC symptoms was assessed through the mean change of Yale–Brown Obsessive-Compulsive (YBOCS) total score. Tolerability was assessed with the Utvalg for Kliniske Undersogelser (UKU) side effect scale and by reporting adverse events. Results: A total of 70 patients were included in the analyses. The withdrawal rate was 21.4%, mainly due to adverse events. Mean ± SD final aripiprazole dose was 15.2 ± 5.3 in the completer sample (N = 55). The Y-BOCS mean score decreased from 24.0 ± 4.1 at baseline to 17.1 ± 4.3 at 12 weeks. Treatment response rate (Y-BOCS reduction ≥ 35%) was 41.8%, while partial response rate (Y-BOCS reduction greater than 25% but less than 35% from baseline) accounted for the other 18.2% of patients. Overall, 91.4% of completers had at least 1 adverse effect (tremor, tension/inner unrest, reduced duration of sleep, akathisia). No significant differences emerged comparing aripiprazole efficacy and tolerability between patients treated with lithium or valproate. Conclusion: Our findings show that aripiprazole addition to lithium or valproate can reduce OC symptoms in real-world BD euthymic patients.
机译：背景和目的：阿里普哌唑是一种综合症的双极障碍（BD）和可用数据表明其对血清素再摄取抑制剂抗性强迫症（OCD）患者的临床症状的疗效。因此，AripiPrazole增强到情绪稳定剂可以代表BD患者的合并症患者的有希望的治疗。该研究检测了阿里普哌唑加入锂或丙丙唑的疗效和安全性，用于治疗肠道强迫症患者的痴呆症（OC）症状。材料和方法：这是一个为期12周的前瞻性观察研究。通过耶鲁棕色强迫症（YBOCS）的平均变化来评估AripiPrazole对OC症状的疗效。用utvalg为kliniske underserer（UKU）副作用规模评估耐受性，并通过报告不良事件。结果：分析中共有70名患者。提取率为21.4％，主要是由于不良事件。平均±SD最终AripiPrazole剂量为15.2±5.3，在30±5.3中（n = 55）。 Y-BOCs平均分数从基线24.0±4.1减少到12周的17.1±4.3。治疗响应率（Y-Bocs还原≥35％）为41.8％，而部分响应率（Y-Bocs减少超过25％，但从基线的35％）占18.2％的患者。总体而言，91.4％的完井师至少有1个不利影响（震颤，紧张/内部动荡，减少睡眠时间，akathisia）。没有显着的差异比较锂或丙丙酸钙或丙丙酸酯治疗的患者之间的阿里希哌唑功效和耐受性。结论：我们的研究结果表明，锂锂或丙丙唑类的阿里普哌唑可以减少现实世界BD疗效患者的症状。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号